» Articles » PMID: 27782805

Fucosyllactose and L-fucose Utilization of Infant Bifidobacterium Longum and Bifidobacterium Kashiwanohense

Overview
Journal BMC Microbiol
Publisher Biomed Central
Specialty Microbiology
Date 2016 Oct 27
PMID 27782805
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Human milk oligosaccharides (HMOs) are one of the major glycan source of the infant gut microbiota. The two species that predominate the infant bifidobacteria community, Bifidobacterium longum subsp. infantis and Bifidobacterium bifidum, possess an arsenal of enzymes including α-fucosidases, sialidases, and β-galactosidases to metabolise HMOs. Recently bifidobacteria were obtained from the stool of six month old Kenyan infants including species such as Bifidobacterium kashiwanohense, and Bifidobacterium pseudolongum that are not frequently isolated from infant stool. The aim of this study was to characterize HMOs utilization by these isolates. Strains were grown in presence of 2'-fucosyllactose (2'-FL), 3'-fucosyllactose (3'-FL), 3'-sialyl-lactose (3'-SL), 6'-sialyl-lactose (6'-SL), and Lacto-N-neotetraose (LNnT). We further investigated metabolites formed during L-fucose and fucosyllactose utilization, and aimed to identify genes and pathways involved through genome comparison.

Results: Bifidobacterium longum subsp. infantis isolates, Bifidobacterium longum subsp. suis BSM11-5 and B. kashiwanohense strains grew in the presence of 2'-FL and 3'- FL. All B. longum isolates utilized the L-fucose moiety, while B. kashiwanohense accumulated L-fucose in the supernatant. 1,2-propanediol (1,2-PD) was the major metabolite from L-fucose fermentation, and was formed in equimolar amounts by B. longum isolates. Alpha-fucosidases were detected in all strains that degraded fucosyllactose. B. longum subsp. infantis TPY11-2 harboured four α-fucosidases with 95-99 % similarity to the type strain. B. kashiwanohense DSM 21854 and PV20-2 possessed three and one α-fucosidase, respectively. The two α-fucosidases of B. longum subsp. suis were 78-80 % similar to B. longum subsp. infantis and were highly similar to B. kashiwanohense α-fucosidases (95-99 %). The genomes of B. longum strains that were capable of utilizing L-fucose harboured two gene regions that encoded enzymes predicted to metabolize L-fucose to L-lactaldehyde, the precursor of 1,2-PD, via non-phosphorylated intermediates.

Conclusion: Here we observed that the ability to utilize fucosyllactose is a trait of various bifidobacteria species. For the first time, strains of B. longum subsp. infantis and an isolate of B. longum subsp. suis were shown to use L-fucose to form 1,2-PD. As 1,2-PD is a precursor for intestinal propionate formation, bifidobacterial L-fucose utilization may impact intestinal short chain fatty acid balance. A L-fucose utilization pathway for bifidobacteria is suggested.

Citing Articles

2'-Fucosyllactose as a prebiotic modulates the probiotic responses of .

Du J, Yang H Curr Res Food Sci. 2025; 10:100975.

PMID: 39906504 PMC: 11791163. DOI: 10.1016/j.crfs.2025.100975.


Precision biotic as an effective replacement of hydrolyzed yeast and butyrate in antibiotic free diets of broiler chickens raised under field conditions.

Bortoluzzi C, Ghanbari M, Gonzales J, Bohorquez J, Paredes R, Mauri Y Poult Sci. 2025; 104(2):104664.

PMID: 39805250 PMC: 11770487. DOI: 10.1016/j.psj.2024.104664.


The Bifidogenic Effect of 2'Fucosyllactose Is Driven by Age-Specific Species, Demonstrating Age as an Important Factor for Gut Microbiome Targeted Precision Medicine.

Firrman J, Deyaert S, Mahalak K, Liu L, Baudot A, Joossens M Nutrients. 2025; 17(1.

PMID: 39796584 PMC: 11723031. DOI: 10.3390/nu17010151.


Human Milk Oligosaccharides: Decoding Their Structural Variability, Health Benefits, and the Evolution of Infant Nutrition.

Duman H, Bechelany M, Karav S Nutrients. 2025; 17(1.

PMID: 39796552 PMC: 11723173. DOI: 10.3390/nu17010118.


Investigation on L-rhamnose metabolism of subsp. DSM 20001 and its propionate-containing fermentates.

Elvan Gezer M, Gravlund Fonss K, Bambace M, Marietou A, Sandberg Overby S, Sundekilde U Appl Environ Microbiol. 2024; 91(1):e0161324.

PMID: 39692501 PMC: 11784251. DOI: 10.1128/aem.01613-24.


References
1.
Egan M, OConnell Motherway M, Kilcoyne M, Kane M, Joshi L, Ventura M . Cross-feeding by Bifidobacterium breve UCC2003 during co-cultivation with Bifidobacterium bifidum PRL2010 in a mucin-based medium. BMC Microbiol. 2014; 14:282. PMC: 4252021. DOI: 10.1186/s12866-014-0282-7. View

2.
Schell M, Karmirantzou M, Snel B, Vilanova D, Berger B, Pessi G . The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc Natl Acad Sci U S A. 2002; 99(22):14422-7. PMC: 137899. DOI: 10.1073/pnas.212527599. View

3.
Louis P, Hold G, Flint H . The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014; 12(10):661-72. DOI: 10.1038/nrmicro3344. View

4.
Turroni F, Bottacini F, Foroni E, Mulder I, Kim J, Zomer A . Genome analysis of Bifidobacterium bifidum PRL2010 reveals metabolic pathways for host-derived glycan foraging. Proc Natl Acad Sci U S A. 2010; 107(45):19514-9. PMC: 2984195. DOI: 10.1073/pnas.1011100107. View

5.
Liu S, Ren F, Zhao L, Jiang L, Hao Y, Jin J . Starch and starch hydrolysates are favorable carbon sources for bifidobacteria in the human gut. BMC Microbiol. 2015; 15:54. PMC: 4349234. DOI: 10.1186/s12866-015-0362-3. View